Calcimedica announces presentations at two upcoming healthcare investment conferences

La jolla, calif. , july 8, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("crac") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that rachel leheny, ph.d.

CALC Ratings Summary

CALC Quant Ranking